Desensitization to thalidomide in a patient with multiple myeloma

Area of Science:

• Dermatology
• Oncology
• Clinical Pharmacology

Background:

• Cutaneous reactions are common with thalidomide therapy, affecting nearly half of patients.
• Thalidomide is a crucial treatment for multiple myeloma.

Observation:

• A 65-year-old woman with multiple myeloma presented with fever and a generalized, itchy maculopapular rash after two days of 100 mg oral thalidomide.
• Standard allergy tests (skin prick and patch tests) for thalidomide were negative.
• An oral provocation test confirmed thalidomide as the cause of the reaction.

Findings:

• The patient underwent an oral desensitization protocol due to the necessity of thalidomide for her multiple myeloma.
• Within five days, the patient successfully tolerated 100 mg of oral thalidomide.
• This represents the first reported case of successful thalidomide desensitization for cutaneous adverse reactions.

Implications:

• Oral desensitization can be a viable strategy for managing necessary thalidomide treatment in patients experiencing cutaneous adverse reactions.
• This approach may improve treatment adherence and outcomes for multiple myeloma patients requiring thalidomide.
• Further research into desensitization protocols for thalidomide-induced reactions is warranted.